Local and systhemic immunotherapy for bladder cancer: from bench to bedside

被引:0
|
作者
Carballido, Joaquin A. [1 ]
Vazquez Alba, David [1 ]
Rodriguez Monsalve, Maria [1 ]
机构
[1] Univ Autonoma Madrid, Fac Med, Serv & Catedra Urol, Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
来源
ARCHIVOS ESPANOLES DE UROLOGIA | 2020年 / 73卷 / 10期
关键词
Transitional cell bladder carcinom; Immunology and bladder cancer; Immunotherapy; Bacillus Calmette-Guerin; BCG Mechanism of action; BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL-CARCINOMA; BIOLOGICAL RESPONSE MODIFIERS; BLOOD MONONUCLEAR-CELLS; NATURAL-KILLER ACTIVITY; T1 PAPILLARY CARCINOMA; TUMOR-NECROSIS-FACTOR; HIGH-RISK TA; INTRAVESICAL BCG; UROTHELIAL CARCINOMA;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Therapeutic approaches for treatment of urothelial transitional cell carcinoma based on immune system modulation, as well as the contribution of introvesical Bacillus de Calmette-Guerin (BCG) and the recent incorporation of checkpoint inhibitors had found irrefutable proofs of concept for the indication of antitumoral immunontherapy in such tumors. Its extension and development at the present time covers all the locations of the wide spectrum of presentation and evolution of these tumors. Nowadays, apart for the low grade non muscle-invasive tumors, we are facing an unpredictable development of antitumoral immunotherapy in bladder cancer not only as an option in the primary treatment, but also in other scenarios such as non-responders when it comes to BCG, or the situation of ineligibility for systemic chemotherapy indication. The main objective of this review article is trying to translate the current basic mechanisms involved in different phases of transitional cell carcinomas antitumoral response, regardless of whether they are muscle-invasive or not, and to establish the rationale for their therapeutic intravesical or systemic administration. The role of the interactions established between urothelial tumor cells and the cellular and molecular elements of the immune system of patients is described, incorporating the relevant and recent advances in immunobiology and the molecular characterization of these tumors that will undoubtedly introduce far-reaching modifications in therapeutic regimes that will contrast with the traditional options available. Investigational lines that are already active in the clinical research phase with BCG and, checkpoints inhibitors of the immune response are also analyzed, highlighting the need to find predictive response markers as a real option for treatments personalization. The approach to the knowledge of the individual reactivity of the immune system of each patient as a determining factor to achieve it is proposed.
引用
收藏
页码:879 / 894
页数:16
相关论文
共 50 条
  • [21] Immunotherapy for Recurrent Glioma-From Bench to Bedside
    Pu, Yi
    Zhou, Guanyu
    Zhao, Kejia
    Chen, Yaohui
    Shen, Shensi
    CANCERS, 2023, 15 (13)
  • [22] Natural killer cell immunotherapy: from bench to bedside
    Domogala, Anna
    Madrigal, J. Alejandro
    Saudemont', Aurore
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [23] Immunotherapy in Alzheimer's Disease: From the Bench to the Bedside
    Diniz, Breno S.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2024, 32 (05): : 584 - 585
  • [24] Pancreatic cancer: from bench to bedside
    Ma, Yaokai
    Wu, Qing
    Li, Xin
    Gu, Xiaoqiang
    Xu, Jiahua
    Yang, Jinzu
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (23)
  • [25] Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside
    Lizardo, Darleny Y.
    Kuang, Chaoyuan
    Hao, Suisui
    Yu, Jian
    Huang, Yi
    Zhang, Lin
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1874 (02):
  • [26] microRNAs in Cancer: From Bench to Bedside
    Cortez, Maria Angelica
    Ivan, Cristina
    Zhou, Peng
    Wu, Xue
    Ivan, Mircea
    Calin, George Adrian
    ADVANCES IN CANCER RESEARCH, VOL 108, 2010, 108 : 113 - 157
  • [27] Cancer research from the bench to the bedside
    Wiestler, O.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S2 - S2
  • [28] Cancer genomics: from bench to bedside
    Nakamura, Yusuke
    CLINICAL & EXPERIMENTAL METASTASIS, 2007, 24 (04) : 211 - 212
  • [29] Hypoxia and Cancer: From Bench to Bedside
    Wang, Lingzhi
    Zhou, Qingyu
    CANCERS, 2023, 15 (09)
  • [30] Cancer proteomics: from bench to bedside
    J F Timms
    British Journal of Cancer, 2008, 99 (4) : 679 - 679